


MetiMedi
Biotechnology Research • Imi-ro 40, Uiwang-si, Korea, Republic of • 1-10 Employees
Company overview
| Headquarters | Imi-ro 40, Uiwang-si, Gyeonggi-do 16006, KR |
| Phone number | +8220240426 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2016 |
| Employees | 1-10 |
| Socials |
Key Contact at MetiMedi
Hwan Mook Kim
Founder And Chief Executive Officer
About MetiMedi
MetiMedi, a bio pharmaceutical company based in South Korea, is at the forefront of cutting-edge research in immuno-oncology. The company is committed to developing a unique platform technology that addresses the unmet needs of solid cancer therapies and beyond. By targeting specific cellular metabolic reprogramming in tumor cells, MetiMedi's immunotherapy leads to tumor necroptosis and immune activation, with exceptional safety. Phase 2 clinical studies with METI-101 for refractory metastatic colorectal cancer have demonstrated efficacy and safety.
MetiMedi revenue & valuation
| Annual revenue | $513,330 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,700,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
MetiMedi has 2 employees across 2 departments.
Departments
Number of employees
Funding Data
MetiMedi has never raised funding before.
MetiMedi Tech Stack
Discover the technologies and tools that power MetiMedi's digital infrastructure, from frameworks to analytics platforms.
Analytics
JavaScript libraries
Reverse proxies
JavaScript libraries
Programming languages
Miscellaneous
Font scripts
SSL/TLS certificate authorities
JavaScript libraries
Databases
Ecommerce
CDN
Frequently asked questions
4.8
40,000 users



